185 related articles for article (PubMed ID: 22418908)
1. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
Menne J; Izzo JL; Ito S; Januszewicz A; Katayama S; Chatzykirkou C; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G; Haller H;
J Hypertens; 2012 Apr; 30(4):811-8; discussion 818. PubMed ID: 22418908
[TBL] [Abstract][Full Text] [Related]
2. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
[TBL] [Abstract][Full Text] [Related]
3. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
Haller H; Ito S; Izzo JL; Januszewicz A; Katayama S; Menne J; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G;
N Engl J Med; 2011 Mar; 364(10):907-17. PubMed ID: 21388309
[TBL] [Abstract][Full Text] [Related]
4. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
Ruggenenti P; Perna A; Ganeva M; Ene-Iordache B; Remuzzi G;
J Am Soc Nephrol; 2006 Dec; 17(12):3472-81. PubMed ID: 17082240
[TBL] [Abstract][Full Text] [Related]
5. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.
Fogari R; Derosa G; Zoppi A; Rinaldi A; Preti P; Lazzari P; Mugellini A
Hypertens Res; 2008 Jan; 31(1):43-50. PubMed ID: 18360017
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.
Omboni S; Malacco E; Mallion JM; Volpe M; Zanchetti A;
J Hypertens; 2012 Jul; 30(7):1468-77. PubMed ID: 22573127
[TBL] [Abstract][Full Text] [Related]
7. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.
Fogari R; Malamani G; Corradi L; Mugellini A; Preti P; Zoppi A; Derosa G
Adv Ther; 2010 Jan; 27(1):48-55. PubMed ID: 20174905
[TBL] [Abstract][Full Text] [Related]
8. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
9. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
[TBL] [Abstract][Full Text] [Related]
10. Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients.
Weir MR; Hollenberg NK; Remuzzi G; Zappe DH; Meng X; Parving HH
J Hypertens; 2011 Oct; 29(10):2031-7. PubMed ID: 21841500
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
12. Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.
Kato J; Yokota N; Tamaki N; Kariya S; Kita T; Ayabe T; Eto T; Kitamura K
Hypertens Res; 2011 Mar; 34(3):331-5. PubMed ID: 21124326
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
Zannad F; Fay R
Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
[TBL] [Abstract][Full Text] [Related]
14. Preventing microalbuminuria in type 2 diabetes.
Ruggenenti P; Fassi A; Ilieva AP; Bruno S; Iliev IP; Brusegan V; Rubis N; Gherardi G; Arnoldi F; Ganeva M; Ene-Iordache B; Gaspari F; Perna A; Bossi A; Trevisan R; Dodesini AR; Remuzzi G;
N Engl J Med; 2004 Nov; 351(19):1941-51. PubMed ID: 15516697
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
16. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
Omboni S; Malacco E; Mallion JM; Volpe M
Drugs Aging; 2012 Dec; 29(12):981-92. PubMed ID: 23179896
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients.
Böhm M; Ewald S;
Curr Med Res Opin; 2006 Jul; 22(7):1375-80. PubMed ID: 16834836
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.
Punzi H; Neutel JM; Kereiakes DJ; Shojaee A; Waverczak WF; Dubiel R; Maa JF
Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):209-21. PubMed ID: 20519261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
